26 LANDSDOWNE STREET, CAMBRIDGE, MA
Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
Unregistered Sales of Equity Securities
Submission of Matters to a Vote of Security Holders
Reports First Quarter 2025 Financial Results and Recent Business Highlights
Annual Report to Security Holders
Announces Pricing of Underwritten Offering
Beam Therapeutics Reports Positive BEAM-302 Data in AATD Phase 1/2 Trial
Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus